Spread the love

A recent study from the Division of Infection and Immunity, University College London, London, UK shows that The kinase p38 activated by the metabolic regulator AMPK and scaffold TAB1 drives the senescence of human T cells.” This study was published in the August 24  2014 Nature Immunology  by Prof Arne N AkbarAlessio Lanna and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Mechanistic and therapeutic insights into rejuvenating ageing immune cells in Cancer patients: Anti-cancer drug Campothecin (CPT) decreases telomerase activity and promotes senescence of human T cells via up regulation of its target gene. Campothecin, by decreasing telomerase activity in immune cells, it may accelerate ageing-associated decline in immune function.  Together, this finding may aid in devising a strategy to prevent accelerated ageing of immune cells in cancer patients.

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, L., Mechanistic and therapeutic insights into rejuvenating ageing immune cells in Cancer patients: Anti-cancer drug Campothecin (CPT) decreases telomerase activity and promotes senescence of human T cells via up regulation of its target gene, 6/September/2014,  10.26 am,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation


Spread the love